Common Stock, $0.0001 par value per share
- Symbol
- ERAS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
Erasca, Inc.
ERASNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs.…
Company context
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Current securities
Registered securities in this filing
Erasca, Inc. · 8-K · Filed 2026-10-16
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 15, 2026, Erasca, Inc. (the Company) decided to realign its leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. Responsibilities currently overseen by the Chief Operating Officer are transitioning to other members of the Company’s leadership team in order to streamline the Company’s reporting structure. Accordingly, the employment of Nicholas (Nik) Chetwyn, Ph. D., the Company’s Chief Operating Officer, will terminate effective November 2, 2026.